Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MRD-Guided Abbreviation of Bendamustine and Rituximab Chemotherapy in Combination With Copanlisib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT04155840 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04155840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04155840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MRD-Guided Abbreviation of Bendamustine and Rituximab Chemotherapy in Combination With Copanlisib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2020
Completion date
March 16, 2021
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, lymphoid leukemia, non-hodgkin's lymphoma, small lymphocytic lymphoma